Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Periodontitis and COVID-19: immunological characteristics, related pathways, and association
Both periodontitis and Coronavirus disease 2019 (COVID-19) pose grave threats to public
health and social order, endanger human life, and place a significant financial strain on the …
health and social order, endanger human life, and place a significant financial strain on the …
Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry
Q Tong, G Liu, X Sang, X Zhu, X Fu, C Dou… - PLoS …, 2023 - journals.plos.org
The rapid emergence of SARS-CoV-2 variants of concern, the complexity of infection, and
the functional redundancy of host factors, underscore an urgent need for broad-spectrum …
the functional redundancy of host factors, underscore an urgent need for broad-spectrum …
[HTML][HTML] Multi-label multi-class COVID-19 Arabic Twitter dataset with fine-grained misinformation and situational information annotations
R Obeidat, M Gharaibeh, M Abdullah… - PeerJ Computer …, 2022 - peerj.com
Since the inception of the current COVID-19 pandemic, related misleading information has
spread at a remarkable rate on social media, leading to serious implications for individuals …
spread at a remarkable rate on social media, leading to serious implications for individuals …
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the …
AN Barbosa, A Chebabo, C Starling, C Pérez… - Annals of Clinical …, 2023 - Springer
Background Since the beginning of the COVID-19 pandemic, therapeutic options for treating
COVID-19 have been investigated at different stages of clinical manifestations. Considering …
COVID-19 have been investigated at different stages of clinical manifestations. Considering …
Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity …
AH Wei, L Zeng, L Wang, L Gui, WT Zhang… - Frontiers in …, 2023 - frontiersin.org
Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment
of COVID-19 in China, however, limited real-world data exists regarding their effectiveness …
of COVID-19 in China, however, limited real-world data exists regarding their effectiveness …
Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS‐COV‐2 targeting main protease and papain‐like protease
S Choudhary, S Nehul, A Singh, PK Panda… - IUBMB …, 2024 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may be over, but its variants continue to …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may be over, but its variants continue to …
Antiviral Effect of 5′-Arylchalcogeno-3-Aminothymidine Derivatives in SARS-CoV-2 Infection
AR Tucci, RM da Rosa, AS Rosa, O Augusto Chaves… - Molecules, 2023 - mdpi.com
The understanding that zidovudine (ZDV or azidothymidine, AZT) inhibits the RNA-
dependent RNA polymerase (RdRp) of SARS-CoV-2 and that chalcogen atoms can …
dependent RNA polymerase (RdRp) of SARS-CoV-2 and that chalcogen atoms can …
Targeting host-virus interactions: in silico analysis of the binding of human milk oligosaccharides to viral proteins involved in respiratory infections
AA Mahaboob Ali, A Vishal, EJR Nelson - Scientific Reports, 2024 - nature.com
Respiratory viral infections, a major public health concern, necessitate continuous
development of novel antiviral strategies, particularly in the face of emerging and re …
development of novel antiviral strategies, particularly in the face of emerging and re …
Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story
P Panagopoulos, V Petrakis, G Trypsianis… - Journal of …, 2022 - Taylor & Francis
A number of treatment options have been evaluated in order to prevent the severe
progression of COVID-19 pneumonia eventually in patients with increased risk due to …
progression of COVID-19 pneumonia eventually in patients with increased risk due to …